ADICET Bio, Inc. (ACET) FinancialsACETADICET Bio, Inc.

Evaluating the bottom line, ADICET Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -78.08%, provide a clear picture of how effectively ACET converts its operational activities into shareholder value.

In the context of the broader market, ACET competes directly with industry leaders such as GOSS and ACRV. With a market capitalization of $78.45M, it holds a significant position in the sector. When comparing efficiency, ACET's gross margin of N/A stands against GOSS's 100.00% and ACRV's N/A. Such benchmarking helps identify whether ADICET Bio, Inc. is trading at a premium or discount relative to its financial performance.

Adicet Bio has reported a consistent net loss, with the latest figures showing a loss of $30.5 million for Q4 2025. The company's EPS is currently at -1.99, indicating ongoing financial challenges. The current ratio remains strong at 6.71, suggesting good short-term liquidity.